Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Evolutionary Medicine, Shiga Medical Center Research Institute, Shiga, Japan.
Cancer Res. 2017 Nov 15;77(22):6131-6143. doi: 10.1158/0008-5472.CAN-17-1800. Epub 2017 Sep 26.
Hepatocellular carcinoma (HCC) originates from regenerating liver cells with genetic alterations in chronically inflamed liver. Ductal cells and hepatocytes proliferate for liver regeneration, and proliferating ductal cells (PDC) derived from bile ductules have long been considered putative liver stem/progenitor cells and candidate cellular origins of HCC. The potential of PDC as tumor-originating cells, however, remains controversial in contrast to accumulating evidence that HCC originates from hepatocytes. Here, we demonstrate that PDCs expressing the established surface and cancer stem cell marker EpCAM give rise to HCC in inflamed liver. EpCAM-expressing PDCs were specifically labeled in newly developed Epcam mice and traced in a chemically induced liver injury model. Stepwise accumulation of genetic alterations in EpCAM-positive cells was induced by the mutagenesis activity of activation-induced cytidine deaminase using conditional transgenic mice. Lineage-tracing experiments revealed that labeled PDC differentiated into cholangiocytes, but not into hepatocytes, in the chemically damaged liver. Nevertheless, EpCAM-positive PDC with genetic alterations gave rise to HCC after 8 months of chemical administration. PDC-derived HCC showed histologic characteristics of concomitant ductule-like structures resembling human cholangiolocellular carcinoma (CLC) and exhibited serial transitions from PDC-like CLC cells to hepatocyte-like HCC cells. The Wnt signaling pathway was specifically upregulated in the CLC components of PDC-derived HCC. Our findings provide direct experimental evidence that EpCAM-expressing PDC could be a cellular origin of HCC, suggesting the existence of stem/progenitor-derived hepatocarcinogenesis. .
肝细胞癌 (HCC) 源自慢性炎症肝脏中具有遗传改变的再生肝细胞。胆管细胞和肝细胞增殖以进行肝脏再生,而来源于胆管小管的增殖胆管细胞 (PDC) 长期以来一直被认为是潜在的肝干细胞/祖细胞和 HCC 的候选细胞起源。然而,与越来越多的证据表明 HCC 源自肝细胞相反,PDC 作为肿瘤起始细胞的潜力仍存在争议。在这里,我们证明表达已建立的表面和癌症干细胞标志物 EpCAM 的 PDC 在炎症性肝脏中引发 HCC。新开发的 Epcam 小鼠中特异性标记表达 EpCAM 的 PDC,并在化学诱导的肝损伤模型中进行追踪。使用条件性转基因小鼠,通过激活诱导的胞嘧啶脱氨酶的诱变活性,在 EpCAM 阳性细胞中逐步诱导遗传改变的积累。谱系追踪实验表明,标记的 PDC 在化学损伤的肝脏中分化为胆管细胞,而不是肝细胞。然而,具有遗传改变的 EpCAM 阳性 PDC 在化学给药 8 个月后会引发 HCC。PDC 衍生的 HCC 表现出与人类胆管细胞癌 (CLC) 相似的伴有小管样结构的组织学特征,并表现出从 PDC 样 CLC 细胞到肝细胞样 HCC 细胞的连续转变。Wnt 信号通路在 PDC 衍生的 HCC 的 CLC 成分中特异性上调。我们的研究结果提供了直接的实验证据,表明表达 EpCAM 的 PDC 可能是 HCC 的细胞起源,提示存在干细胞/祖细胞来源的肝癌发生。